EDISON EQUITY RESEARCH: ATHERSYS
October 25 2015 - 11:29PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ATHERSYS - ONE DOOR CLOSES, ANOTHER
ONE OPENS
Today, Athersys announced that the agreement between the company
and Chugai to develop and commercialize MultiStem in Japan has
ended following the failure of negotiations to modify the financial
terms of the agreement and to decide on a development strategy.
However, Athersys also announced that it has already signed a
letter of intent with another Japanese company to develop and
commercialize MultiStem in Japan in ischemic stroke and other
areas.
Athersys is a US biotech company developing MultiStem (allogeneic,
bone marrow-derived stem cells). A Phase II trial with MultiStem in
ischemic stroke has completed, while further studies in AMI (Phase
II) and ARDS (Phase IIa) are planned.
To view our full report, please click here
Click here to view all of Edison
Investment Research’s published reports
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024